Categories: News

Femasys Inc. to Participate in Upcoming January Investor Conferences

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

Participation and presentation details are below:

  • LifeSci Partners Corporate Access Event:
    • Kathy Lee-Sepsick, President, Chief Executive Officer and Founder, will present on a panel entitled, “The Role of Gender Equality in Changing the Landscape of Life Sciences Innovation & Investment” on Thursday, January 6th, 12:00 pm ET.
    • The Femasys management team will be available for 1×1 meetings with interested investors during January 6th -7th. Register here to submit a meeting request or to hear the panel discussion.
  • H.C. Wainwright BioConnect Conference:
    • Femasys will present at the H.C. Wainwright BioConnect Conference and a recording of the presentation will be accessible beginning January 10th at 7:00 am ET. To listen to the event, please click here to register and access the webcast

About Femasys

Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com

Femasys Inc.
Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com

Staff

Recent Posts

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…

3 hours ago

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…

3 hours ago

Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based…

3 hours ago

The Naderi Center Announces the Rise of “Facial Harmony” as 2025’s Leading Trend in Aesthetic Surgery and Dermatology

From combination surgeries to advanced skin therapies, The Naderi Center outlines how patients nationwide are…

3 hours ago

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

6 hours ago